ASCO Annual MeetingASCO
May 29 – Jun 2, 2026Chicago, IL
American Society of Clinical Oncology — the single biggest catalyst event for oncology. Late-breaking trial readouts move stocks daily.
Calendar
Conferences
The meetings that move biotech and pharma — what's coming, and what just happened.
Upcoming
BIO International ConventionBIO
Jun 8–11, 2026Boston, MA
The largest global biotech partnering meeting. 20,000+ attendees, heavy on BD&L and emerging biotech.
EHA CongressEHA
Jun 11–14, 2026Milan, Italy
European Hematology Association — the year's biggest heme-onc readouts (CAR-T, bispecifics, MM, AML, CLL).
ADA Scientific SessionsADA
Jun 19–23, 2026Chicago, IL
American Diabetes Association — the obesity & cardiometabolic readout window. GLP-1, GIP/GLP-1, oral incretins, kidney outcomes.
ESMO CongressESMO
Oct 16–20, 2026Madrid, Spain
European oncology's flagship. Pivotal Phase 3 reads in NSCLC, breast, GI; perioperative & ADC data dominate.
AHA Scientific SessionsAHA
Nov 7–10, 2026New Orleans, LA
American Heart Association — late-breaking CV outcomes trials. Lipid, HF, anticoagulation, and now obesity-CV crossover.
RSNA Annual MeetingRSNA
Nov 29 – Dec 3, 2026Chicago, IL
Radiological Society of North America — imaging, AI radiology, and diagnostics from GE HealthCare, Siemens, Philips, and AI startups.
CTADCTAD
Dec 1–4, 2026San Diego, CA
Clinical Trials on Alzheimer's Disease — primary venue for anti-amyloid and tau readouts (Lilly, Eisai/Biogen, Roche).
ASH Annual MeetingASH
Dec 5–8, 2026Orlando, FL
American Society of Hematology — the year's defining heme/cell-therapy data. CAR-T durability, bispecifics, gene therapy in SCD.
J.P. Morgan Healthcare ConferenceJPM
Jan 11–14, 2027San Francisco, CA
The industry's marquee deal-making and strategy-setting week. Public biotechs and pharmas pre-announce earnings, deals, and pipeline priorities for the year.
Past meetings — insights & launches
J.P. Morgan Healthcare Conference
Jan 12–15, 2026 · San Francisco, CAYear-opening agenda-setter. M&A chatter, 2026 guidance, and obesity-pipeline jockeying dominated.
Key insights
- →Obesity remained the single biggest strategic theme — oral GLP-1s and combo agents drew most pipeline questions.
- →Tone on M&A warmed vs 2025: more mid-cap tuck-ins, fewer mega-deals, with bolt-ons in ADC and radiopharma leading.
- →ADC and radiopharma platforms reset valuations after a soft 2025 — sponsors leaned into next-gen payload and isotope stories.
What big pharma unveiled
Eli Lilly — Reiterated orforglipron filing timing
Positioned the oral GLP-1 as the access-expansion lever for 2026–27.
Novo Nordisk — Detailed CagriSema repositioning
Reframed cardio-metabolic combo strategy after the prior Ph3 miss.
AstraZeneca — Showcased Dato-DXd + Enhertu lifecycle
Expanded ADC franchise narrative across breast, lung, and GI.
Merck — Keytruda LOE bridge plan
Pushed subcutaneous Keytruda + late-stage I/O combos as the post-LOE story.
ASH Annual Meeting
Dec 6–9, 2025 · Orlando, FLDefining hem-onc readouts of the year — CAR-T durability, off-the-shelf cell therapy, and bispecific combos in MM and lymphoma.
Key insights
- →Bispecifics moved earlier in multiple myeloma — talquetamab and teclistamab combos reset frontline thinking.
- →Allogeneic CAR-T showed clearer signs of life in select indications after years of skepticism.
- →Sickle-cell gene therapies (Casgevy, Lyfgenia) drew more real-world access scrutiny than efficacy debate.
What big pharma unveiled
Johnson & Johnson — Talquetamab/Tecvayli frontline-shift data
Combo and earlier-line MM datasets reinforced J&J's heme franchise.
AstraZeneca — Calquence + venetoclax in CLL
Positioned to challenge BTK/BCL2 standards of care.
Pfizer — Elrexfio updates in MM
Multi-cohort durability data supporting label expansion.
AbbVie — Epkinly combo data in DLBCL
Earlier-line bispecific positioning vs CAR-T.
ESMO Congress
Oct 17–21, 2025 · Berlin, GermanyEuropean oncology's biggest stage — ADC competition heated up and perioperative I/O kept expanding.
Key insights
- →ADC space got more crowded: HER2, TROP2, and HER3 each had multiple credible programs with overlapping data.
- →Perioperative checkpoint inhibition kept expanding into earlier disease stages across NSCLC and GI.
- →China-originated assets continued to dominate the in-licensing conversation.
What big pharma unveiled
AstraZeneca / Daiichi Sankyo — Dato-DXd + Enhertu lifecycle datasets
Lung and breast updates supporting category leadership.
Merck — Keytruda perioperative expansions
Pushed into more early-stage settings to extend the franchise.
Roche — Inavolisib follow-up in HR+/HER2- breast
Reinforced PI3K-directed combo strategy.
Bristol Myers Squibb — Opdivo + chemo perioperative NSCLC
Competitive read vs Keytruda in resectable disease.
ASCO Annual Meeting
May 30 – Jun 3, 2025 · Chicago, ILOncology's flagship meeting — bispecifics, ADC pile-up, and the year's most-watched perioperative reads.
Key insights
- →Bispecifics broadened beyond hematology into solid-tumor proof-of-concept datasets.
- →Tumor-agnostic biomarker strategies (MSI-H, HER2-low, KRAS) continued to redraw label boundaries.
- →AI-driven trial design and digital pathology had a notably larger session footprint than in prior years.
What big pharma unveiled
Eli Lilly — Imlunestrant + abemaciclib in HR+ breast
Positioned oral SERD + CDK4/6 as a post-AI standard.
Pfizer — Vepdegestrant + post-CDK4/6 strategy
PROTAC degrader narrative in HR+ breast.
AstraZeneca — Tagrisso + savolitinib EGFR-mut NSCLC
Combo strategy in MET-amplified resistance.
Merck — Keytruda + Padcev frontline urothelial
Continued displacement of platinum-based standard of care.
J.P. Morgan Healthcare Conference
Jan 13–16, 2025 · San Francisco, CAObesity dominated. Radiopharma and ADC platforms drove the deal narrative; mood on small-cap biotech tone improved modestly.
Key insights
- →Obesity pipelines (oral GLP-1, amylin, GIP/GLP-1, triple agonists) were the defining strategic question.
- →Radiopharmaceuticals emerged as the most active bolt-on M&A category.
- →AI/digital-biology platform partnerships were less hyped, more contractual — moving past the 2023–24 narrative peak.
What big pharma unveiled
Eli Lilly — Orforglipron Ph3 readout framing
Set up the oral GLP-1 launch narrative for the year.
Novo Nordisk — Amycretin early data tease
Positioned next-gen obesity asset behind CagriSema.
Johnson & Johnson — Intra-Cellular acquisition (~$14.6B)
Largest pharma deal announced at the conference, anchored CNS franchise.
Eli Lilly — Scancell / Scorpion deal posture
Reinforced oncology bolt-on strategy alongside obesity.